A Systematic Review and Network Meta‐Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer

BACKGROUND. Regorafenib at different dosing strategies and TAS‐102 are treatment options for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative effectiveness evidence supporting these different strategies. MATERIALS AND METHODS. We searched different databases for r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Sonbol, Mohamad Bassam, Benkhadra, Raed, Wang, Zhen, Firwana, Belal, Walden, Daniel J., Mody, Kabir, Hubbard, Joleen M., Murad, M. Hassan, Ahn, Daniel H., Bekaii‐Saab, Tanios
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2019
Aiheet:
Gastrointestinal Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738316/
https://ncbi.nlm.nih.gov/pubmed/31164455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0189
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia